ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GPL Graft Polymer (uk) Plc

0.525
0.08 (17.98%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Graft Polymer (uk) Plc LSE:GPL London Ordinary Share GB00BMD1Z199 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.08 17.98% 0.525 24,225,150 15:22:18
Bid Price Offer Price High Price Low Price Open Price
0.50 0.55 0.60 0.445 0.445
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 45.63M -2.52M -0.0202 -0.26 648.77k
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:02 O 90,909 0.55 GBX

Graft Polymer (uk) (GPL) Latest News

Graft Polymer (uk) (GPL) Discussions and Chat

Graft Polymer (uk) Forums and Chat

Date Time Title Posts
21/6/202410:49Grafting Graft Polymer294
29/5/202420:06Beware of this scam7

Add a New Thread

Graft Polymer (uk) (GPL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-06-21 15:29:040.5590,909500.00O
2024-06-21 15:24:560.55100,000550.00O
2024-06-21 15:24:190.55170,000935.00O
2024-06-21 15:23:510.55200,0001,099.00O
2024-06-21 15:15:420.54276,7521,500.00O

Graft Polymer (uk) (GPL) Top Chat Posts

Top Posts
Posted at 21/6/2024 09:20 by Graft Polymer (uk) Daily Update
Graft Polymer (uk) Plc is listed in the Business Services, Nec sector of the London Stock Exchange with ticker GPL. The last closing price for Graft Polymer (uk) was 0.45p.
Graft Polymer (uk) currently has 124,763,966 shares in issue. The market capitalisation of Graft Polymer (uk) is £648,773.
Graft Polymer (uk) has a price to earnings ratio (PE ratio) of -0.26.
This morning GPL shares opened at 0.45p
Posted at 15/6/2024 09:05 by pwhite73
GPL is falling for a number of reasons.

1. The company is main listed therefore it cannot raise further equity until it has a market cap of £30 million or unless an exemption from the £30 million is granted by the FCA. If it were to move to the AIM it would need a market cap of £6 million. This is what the following RNS is about but they haven't let on.

RNS 04/06/2024 - "Any equity fundraise would also require the publication of a Financial Conduct Authority approved prospectus by the Company to enable new shares to be admitted to trading on the Main Market of the London Stock Exchange. Further announcements will be made as appropriate regarding this matter."

2. This is also important.

RNS 07/06/2024 - "Currently, the Company is evaluating a shortlist of five entities for potential future commercial collaboration in this space."

You can interpret the statement two ways:-

a) The company has been approached by Pfizer, Eli Lilly, Glaxo, AstraZeneca and Novartis for commercial collaboration which will clearly lead to profit or:-

b) The company is intending to approach Pfizer, Eli Lilly, Glaxo, AstraZeneca and Novartis for collaboration in which case there is no guarantee of commercial collaboration leading to profit.

It is my personal view that b) is the reality and PIs have incorrectly interpreted the RNS.

3. Now this point is technical and I'm willing to be corrected.

RNS 07/05/2024 - "The Company is pleased to announce the grant of patent P-202400066, titled "Dual hydrogel multi-crosslinking haemostatic composition and method of manufacturing thereof", to further strengthen the Company's IP portfolio."

I cannot find this patent anyway either by the number, title of the patent or the name Graftpolymer. Furthermore there are two digits missing from the patent. The first four digits represents the year 2024 the patent is granted then followed by seven digits not five. Below is the link for all patent searches.



Please be careful if you are invested in this stock.
Posted at 10/6/2024 08:16 by citys2874
expect another great day for GPL and KRPZ
Posted at 07/6/2024 13:34 by citys2874
GPL and KRPZ having a great day could seriously rally this afternoon
Posted at 04/6/2024 16:02 by stealive
The only thing that is up is the share price. (Drops mic)
Posted at 31/5/2024 15:50 by royalles
JacksE4 this is the GPL bb mate so please discuss other shares on their own bb if you can,not fair to genuine holders.


Although i do caveat by saying i agree that Baron will likely have a good move next week,but please post there not here.
Posted at 31/5/2024 13:53 by citys2874
great day for GPL and GILD should fly this afternoon
Posted at 31/5/2024 12:17 by bmwman3
Filing of US Provisional Patent for Treatment of Mental Health Disorders Graft Polymer (UK) Plc (LSE: GPL) announces that it has filed a second utility patent application (provisional) with the United States Patent and Trademark Office (USPTO). This application is for the use of the Company's proprietary and patented self-nanoemulsifying drug delivery systems (SNEDDS) platform for the delivery of drugs for the treatment of mental health disorders such as Generalised Anxiety Disorder (GAD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). Patent Filing OverviewThe provisional patent application, titled 'Composition and methods for mental health disorders using a self-nanoemulsifying drug delivery systems (SNEDDS)', covers the innovative application of Graft Polymer's SNEDDS platform to enhance the bioavailability, pharmacokinetics and stability of therapeutics used in the treatment of health disorders such as GAD, MDD and PTSD, many of which have poor solubility leading to suboptimal drug delivery and posing an obstacle to successful formulation. This approach aims to leverage the Company's existing advanced biopolymer expertise to address significant unmet medical needs in addiction therapy.
Posted at 31/5/2024 07:11 by tomboyb
Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

Further Patent Application



Filing of US Provisional Patent for Treatment of Mental Health Disorders



Graft Polymer (UK) Plc (LSE: GPL) announces that it has filed a second utility patent application (provisional) with the United States Patent and Trademark Office (USPTO). This application is for the use of the Company's proprietary and patented self-nanoemulsifying drug delivery systems (SNEDDS) platform for the delivery of drugs for the treatment of mental health disorders such as Generalised Anxiety Disorder (GAD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).





Patent Filing Overview

The provisional patent application, titled 'Composition and methods for mental health disorders using a self-nanoemulsifying drug delivery systems (SNEDDS)', covers the innovative application of Graft Polymer's SNEDDS platform to enhance the bioavailability, pharmacokinetics and stability of therapeutics used in the treatment of health disorders such as GAD, MDD and PTSD, many of which have poor solubility leading to suboptimal drug delivery and posing an obstacle to successful formulation. This approach aims to leverage the Company's existing advanced biopolymer expertise to address significant unmet medical needs in addiction therapy.





Strategic Significance

The filing of this patent follows the announcement, by the Company, on 28 May 2024 relating to the filing of a similar utility patent application (provisional) for the treatment of substance use disorders. It marks further progress in the Company's strategic focus on the healthcare industry, following the disposal of its industrial plastic manufacturing unit, Graft Polymer D.O.O, as announced on 3 May 2024. This disposal has enabled the Company to focus its attention and resources on its Graft Bio division, which represents, in the Directors' opinion, strong prospectivity through its intellectual property (IP), licensing agreements, and sales contracts.





Anthony Tennyson, CEO commented:

"We are delighted to announce further progress in leveraging our existing biopolymer intellectual property for additional important healthcare applications with substantial unmet medical needs."





Enquiries

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director
Email: yifat@graftpolymer.com



Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

 +44 (0) 20 3328 5656
Posted at 30/5/2024 10:14 by sos100
Make up your mind :)

------

bensdad2 - 28 May 2024 - 12:08:52 - 71 of 154 Grafting Graft Polymer - GPL
This share was at 4p one year ago. The last placing was in December 0.6p. That included warrants at 1p.
It looks unlikely that there will be anotherraise, but who knows in these markets? I think this has a lot of legs still from here (written when the price was .24-.25p)
Posted at 28/5/2024 17:14 by blakesmith
Insp got their placing tomorrow time for GpL
Graft Polymer (uk) share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock